LAW FIRM DIRECTORY

Competition

20 Biggest Public Antitrust Deals

No Transaction Value Legal counsels
1 Merger clearance for the acquisition of Shire plc by AbbVie Inc. USD 54.7 billion* Sayenko Kharenko represented AbbVie Inc. and Shire plc; Asters represented AbbVie Inc.
2 Merger control clearance for the merger of equals of Lafarge and Holcim USD 50.1 billion Avellum Partners represented Lafarge and Holcim
3 Merger clearance for concentration in connection with stock-for-stock merger between Omnicom Group, Inc. and Publicis Groupe S.A. USD 35.1 billion Asters represented Publicis Groupe S.A., Omnicom Group, Inc.
4 Merger clearance for the acquisition of the controlling stake of Forest Laboratories Inc. by Actavis PLC USD 28 billion* Sayenko Kharenko represented Actavis PLC and Forest Laboratories Inc.
5 Merger clearance for the acquisition by Bayer of Consumer Care Business of Merck USD 14.2 billion Asters represented Bayer AG, Merck & Co., Inc.
6 Merger clearance for the acquisition of AerCap Holdings N.V. by American International Group, Inc.; and for the acquisition of International Lease Finance Corporation by AerCap Holdings N.V. USD 7.6 billion * Sayenko Kharenko represented AerCap Holdings N.V., International Lease Finance Corporation, American International Group, Inc.
7 Merger clearance for the acquisition by Koch Industries, Inc. of control over Molex Incorporated About EUR 5,5 billion Astersrepresented Koch Industries, Inc., Molex Incorporated
8 Merger clearances for the acquisition by Microsoft Corporation of Nokia Corporation’s devices and services business segment EUR 5,44 billion Asters represented Microsoft Corporation, Nokia Corporation
9 Merger and antitrust clearances for the acquisition by Eli Lilly of Novartis' Animal Health business USD 5.4 billion * Asters represented Eli Lilly and Company; Sayenko Kharenko represented Novartis AG
10 Merger clearance for the indirect acquisition by the Blackstone Group L.P. of 100% shares of Pinafore Holdings B.V., the parent company of Gates Corporation USD 5.4 billion Asters represented The Blackstone Group L.P., Pinafore Holdings B.V.
11 Merger clearance for the acquisition by Nestlé of shares in Galderma Pharma and Galderma International USD 3.6 billion Asters represented Nestlé S.A., Galderma Pharma S.A., Galderma International S.A.S.
12 Merger clearance for the acquisition by LVMH of 77,1296 % stake in Loro Piana and concerted actions of abstention from competition EUR 2,68 billion Asters represented LVMH — Moët Hennessy Louis Vuitton and Loro Piana S.p.A.
13 Merger clearance for the acquisition of the controlling stake of Ranbaxy Laboratories Limited by Sun Pharmaceutical Industries Ltd. USD 3.2 billion * Sayenko Kharenko represented Sun Pharmaceutical Industries Ltd. and Ranbaxy Laboratories Limited
14 Merger clearance for the acquisition by The Carlyle Group L.P. of the Industrial Packaging Group from Illinois Tool Works Inc. USD 3.2 billion Asters represented The Carlyle Group L.P., Illinois Tool Works Inc.
15 Merger  clearance for the acquisition of control over Foster Wheeler AG by AMEC Plc EUR 2,39 billion Avellum Partners represented Foster Wheeler Group; Sayenko Kharenko represented AMEC plc
16 Merger clearance for the acquisition of WILD Flavors GmbH by Archer-Daniels-Midland Company EUR 2.2 billion* Sayenko Kharenko represented Archer-Daniels-Midland Company and WILD Flavors GmbH
17 Merger clearance for the acquisition by Arcelor and Nippon of ThyssenKrupp Steel USA USD 1,55 billion Baker & McKenzie represented Arcelor Mittal USA LLC, Nippon Steel & Sumitomo Metal Corporation and ThyssenKrupp Steel (USA)
18 Merger clearance for the indirect acquisition by Advent International Corporation of shares of Douglas Holding AG USD 1.4 billion Asters represented Advent International Corporation and Douglas Holding AG
19 Merger clearance for the sale by JP Morgan Chase & Co of part of its stake in the portfolio of its One Equity Partners to Lexington Partners LP and Carlyle Group USD 1.4 billion Asters represented Carlyle Group
20 Merger clearance for the acquisition by Aspen Pharmacare Holdings Limited of GlaxoSmithKline Plc EUR 857 million Asters represented Aspen Pharmacare Holdings Limited

Note
Transactions in the table were closed during Q4 2013 – Q1-3 2014.
Transactions marked as confidential are not included into the table.
* — open sources